Adlai Nortye Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANL research report →
Range $31 – $49
Price Chart
About the company
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials.
- CEO
- Yang Lu
- IPO
- 2023
- Employees
- 109
- HQ
- Singapore, SG
Get TickerSpark's AI analysis on ANL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $453.83M
- P/E
- -4.85
- PEG
- -0.07
- P/S
- 25.57
- P/B
- 0.70
- EV/EBITDA
- -18.91
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -113.28%
- Net Margin
- -114.48%
- ROE
- -21.82%
- ROIC
- -9.23%
Latest fiscal year · YoY change
- Revenue
- $5.00M+0.0%
- Gross Profit
- $5.00M+0.0%
- Op Income
- $-35,698,000
- Net Income
- $-35,528,000+31.5%
- EPS
- $-3.33+31.9%
- OCF Growth
- +35.3%
- FCF Growth
- +35.1%
- 52W High
- $17.25
- 52W Low
- $0.88
- 50D MA
- $12.56
- 200D MA
- $11.74
- Beta
- 1.16
- RSI (14)
- 38
- Avg Volume
- 240.40K
No earnings-call transcripts are available for ANL yet.
- Free Float
- 71.2%
- Shares Outstanding
- 53.08M
- Float Shares
- 12.60M
of shares held by institutions
42 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cormorant Asset Management, LP | 3.98M | 0 |
| Ameriprise Financial Inc | 3.31M | ▲ 3.22M |
| Venrock Adviser, LLC | 3.21M | 0 |
| Balyasny Asset Management L.P. | 2.70M | ▼ 366.53K |
| Point72 Asset Management, L.P. | 2.15M | ▲ 8.59K |
| Mpm Bioimpact LLC | 1.96M | ▲ 20.33K |
| Perceptive Advisors LLC | 1.66M | ▼ 132.69K |
| Soleus Capital Management, L.P. | 1.27M | ▲ 866.83K |
| Casdin Capital, LLC | 1.25M | 0 |
| Eventide Asset Management, LLC | 1.07M | ▲ 352.54K |
| Adar1 Capital Management, LLC | 997.36K | ▼ 20.45K |
| Millennium Management LLC | 971.14K | ▲ 163.31K |
Held by 5 ETFs
Biggest fund positions in ANL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 29, 26 | Ji Ping | sell | 214 |
| Sep 30, 26 | Ji Ping | sell | 5,000 |
| Sep 30, 26 | Ji Ping | sell | 5,000 |
| Sep 22, 26 | Ji Ping | sell | 5,000 |
| Aug 24, 26 | Ye Xiaofeng | sell | 6,000 |
| Aug 26, 26 | Ye Xiaofeng | sell | 5,667 |
| Mar 18, 26 | Birgerson Lars Erik | other | 0 |
| Mar 18, 26 | Sawhney Roger | other | 0 |
| Mar 18, 26 | Sawhney Roger | other | 0 |
| Mar 22, 27 | Sawhney Roger | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ANL coverage
Recent articles, reports, and earnings notes.
No research on ANL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANL report →Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium
globenewswire.com · Oct 27
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
globenewswire.com · Oct 15
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
zacks.com · Oct 14
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
globenewswire.com · Sep 30
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Stock Has Consensus Target Price of $29.50 According to Analysts
defenseworld.net · Sep 30
Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC
globenewswire.com · Sep 8
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High?
zacks.com · Aug 18
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
globenewswire.com · Aug 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.